ORTHOPEDIATRICS CORP
OrthoPediatrics is a medical device company headquartered in Warsaw, Indiana. It designs, develops and markets orthopedic implants, instruments and specialized braces for children with orthopedic conditions, serving pediatric orthopedic surgeons, hospitals, medical facilities and patients. Its portfolio includes 87 surgical and bracing systems across trauma and deformity correction, scoliosis, and sports medicine and other procedures. It also provides orthotic and prosthetic clinic services, including non-surgical treatment, and sells enabling technologies for pediatric applications. OrthoPediatrics sells through direct representatives, sales agencies and stocking distributors in the United States and international markets. It uses contract manufacturers for implants and related surgical instruments, while its braces are typically made in-house. The company also operates multiple orthotic and prosthetic clinics.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $KIDS in the last 30 days.
See all $KIDS insider activity →OrthoPediatrics Corp. (KIDS) has fully launched its VerteGlide spinal system for early-onset scoliosis. The company reported strong demand during a limited launch but did not disclose sales figures.
Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.
TD Cowen kept its Buy rating on OrthoPediatrics with a $28 price target, implying a 17.5% upside. The company reported 19% revenue growth in 3Q26, exceeding expectations, and raised its FY26 revenue guidance, citing strong demand and new product launches.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning KIDS (ORTHOPEDIATRICS CORP). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent KIDS coverage spans earnings, financial news and technology.
The launch introduces a new revenue stream but provides no sales data, so impact is uncertain.
Revenue beat and guidance raise underpin further rally.
Analyst upgrade with higher price target.
Stifel kept a Buy rating on OrthoPediatrics with a $27 price target, implying 13.4% upside. The company reported 18.6% revenue growth in 3Q26, exceeding estimates, and achieved positive free cash flow of $1.6 million. Management raised full-year sales guidance, indicating strong operational performance.
Piper Sandler maintained an Overweight rating on OrthoPediatrics with a $30 price target, suggesting 25.9% upside. The company reported Q3 revenue of $72.7M, up 18.6% YoY, exceeding expectations by $4.2M. Analysts highlight strong demand, product expansion, and market growth.
AlphAI scores every news story that mentions KIDS with an AI model for sentiment and relevance, and aggregates insider trades from ORTHOPEDIATRICS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
OrthoPediatrics Corp. (KIDS) has fully launched its VerteGlide spinal system for early-onset scoliosis. The company reported strong demand during a limited launch but did not disclose sales figures.
Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.
TD Cowen kept its Buy rating on OrthoPediatrics with a $28 price target, implying a 17.5% upside. The company reported 19% revenue growth in 3Q26, exceeding expectations, and raised its FY26 revenue guidance, citing strong demand and new product launches.
Stifel kept a Buy rating on OrthoPediatrics with a $27 price target, implying 13.4% upside. The company reported 18.6% revenue growth in 3Q26, exceeding estimates, and achieved positive free cash flow of $1.6 million. Management raised full-year sales guidance, indicating strong operational performance.
Piper Sandler maintained an Overweight rating on OrthoPediatrics with a $30 price target, suggesting 25.9% upside. The company reported Q3 revenue of $72.7M, up 18.6% YoY, exceeding expectations by $4.2M. Analysts highlight strong demand, product expansion, and market growth.
BTIG kept a Buy rating on OrthoPediatrics with a $30 price target, suggesting a 25.9% upside from the last close. The company reported 3Q26 revenues of $72.7M, up 18.6% YoY, and raised its FY26 revenue guidance to $270M-$273M, according to BTIG.
OrthoPediatrics Corp.'s average stock price target increased from $27.5 to $29, with estimates ranging from $23 to $35. This implies a 22% upside based on the Oct. 27 closing price. All 8 analysts rate the stock as Buy or Hold, with 7 Buys and 1 Hold.
OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.
OrthoPediatrics (KIDS) received FDA clearance for its Pediatric Nailing Platform Femur Retrograde Nail System, designed for pediatric trauma and deformity correction. The system is available in diameters from 7 mm to 11 mm and will be released in 2026, with broader commercialization in 2027. The company has used its Pediatric Nailing Platform in approximately 15,000 patients worldwide.
ORTHOPEDIATRICS CORP (KIDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million, Up 19% Year-over-Year WARSAW, Ind., October 27, 2026 -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:
